SM‑04554
Experimental hair loss compound applied to the skin; an early human study showed only a modest gain, not approved.

DETAILED OVERVIEW
What is SM-04554?
SM-04554 is an experimental compound applied to the skin, developed for pattern hair loss. It is not approved as a medicine anywhere, is not available as a routine treatment and is used only within clinical studies, and its further development is uncertain.
It tries to switch on a signalling pathway that plays a key role in how hair follicles form and renew, so that in theory new follicles would develop. In an early human study the hair count rose measurably compared with a preparation without the active ingredient, but the improvement was modest and there is no large confirmatory study, so any benefit is unproven. Mild local redness and itching occurred and it was generally well tolerated, but its long-term safety in humans is not fully explored. It should be avoided in pregnancy and breastfeeding because there are no human data.
Developer
Samumed / Biosplice Therapeutics
Status
Phase 2 trial, modest and mixed result; not approved
Mechanism of action
Topical Wnt/β-catenin pathway activator (regenerative, NOT antiandrogen)
Evidence
Limited, mixed; no confirmatory phase 3
Access
Trial only; not available as a routine treatment
No anecdote collected yet.
Data console
Lab data
Jang J, Song J, Lee H, et al. . Recent updates on Wnt signaling modulators: a patent review (2014-2020). Expert Opin Ther Pat. 2021. (class context: Wnt modulators).
Safety
Side effects, stop signs, contraindications
Side effects · 3
- Local scalp reaction: phase trials reported mild application-site reactions (redness, itching); generally well tolerated, but the full human safety picture is limited.
- Limited and mixed efficacy data: the phase 2 trial showed only MODEST, not clearly robust hair-count increases, and the further development status is uncertain; do not expect confirmed efficacy.
- Modulating the Wnt pathway is a theoretical consideration: the Wnt pathway is active in many tissues; for a local topical agent systemic effect is designed to be minimal, but long-term human safety is not fully characterized.
Contraindications · 3
- Not approved, investigational: no approved indication or dose; not available as a routine treatment.
- Pregnancy and breastfeeding: avoid due to lack of human data.
- Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
Telegram
Have a question about SM‑04554?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.